Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Knight Therapeutics Inc
KHTRF
Primary Symbol:
T.GUD
Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select...
international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:GUD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Post by
Chianchin
on Dec 26, 2022 10:40am
Mugsy and GUD shareholders
Question? Should Mugsy be held laible for promoting GUD to investors beyond the point of investememt logic for ten Years. Mugsy never provided caveat or conditions of concers. Clearly anyone who
...more
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Dec 24, 2022 2:56pm
RE:2nd Biogen AD drug ...
This is truly relevant to GUD financial disaster
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Dec 23, 2022 10:44pm
2nd Biogen AD drug ...
Biogen pulled the plug on the first drug. Now they're working on this one ... safety again in question. As enthusiasm mounts for a new experimental antibody that appears to slow cognitive
...more
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Dec 23, 2022 4:41pm
RE:Shelf Prospectus ...
For ten Years it has been always next Year. Yet nearly one billion in cash badly invested and now borrowing in LATAM depretiating paper. No PP in hard currencies. No buyers to be found for it
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Dec 23, 2022 4:32pm
Shelf Prospectus ...
Comes due in January (I think). Watching for a renewal in Q1. Merry Christmas !!!!
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Dec 23, 2022 11:31am
RE:Ha Ha Ha ... textbook !
The market and investors gets it. you and your aliases do not
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Dec 23, 2022 10:27am
Ha Ha Ha ... textbook !
It's just the way we do it here! All tools available and deployed as it makes sense to do so. You either get it - or you don't ! Happy Holiday's All !!!!
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Post by
Chianchin
on Dec 23, 2022 7:40am
GUD borrowing?
I had anticipated as only a matter of time. This is what usualy happens when a company burnes good cash nearly 1 billion in 8 years and does not make a profits. What is next?
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 23, 2022 7:30am
New Press Release - Knight Therapeutics Closes US$38.5 million Loan with IFC
MONTREAL, Dec. 23, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has closed a five-year, US$38.5 million secured loan denominated in select Latin American currencies with the International...
read article.
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Dec 22, 2022 5:38pm
RE:RE:Here is a repurposing example ...
Well, Mugsy is gone for now. or the scrooge got hold of he/she, the free dinner for mugsy is off the table as no one offered to pitchin. Happy hollydays to all
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Comment by
Chianchin
on Dec 17, 2022 12:42pm
RE:Here is a repurposing example ...
Poor mugsy, lost fortunes for 8 years and still beleives in Paladin lamps and jeene
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Dec 16, 2022 2:32pm
Here is a repurposing example ...
Won't know the full reasoning behind the Exelon purchase but you start investigating like this ... what kind of drug is Exelon ? Cholinesterase inhibitors (Aricept®, Exelon®, Razadyne
...more
(6)
•••
EbbFlow88
X
View Profile
View Bullboard History
Comment by
EbbFlow88
on Dec 16, 2022 2:09pm
RE:RE:RE:RE:Depreciation/Amortization
That's all interesting. I just looked more into ATE. It's not in my wheelhouse or risk tolerance but it can be very interesting piece for knight in the future. "The other trick
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Dec 16, 2022 1:55pm
RE:RE:RE:Depreciation/Amortization
Regarding this comment specifically ... "All things being equal, its a very smart move as we pay less tax but have the cashflow to reinvest. It's also totally legal and conservative of
...more
Prev
...
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >